1. Wang J, Yu Y, Li G, et al. Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients. J Hepatol. 2018; 68:16–24.
Article
2. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018; 67:1560–1599.
Article
3. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006; 295:65–73.
Article
4. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006; 130:678–686.
Article
5. Wang J, Shen T, Huang X, et al. Serum hepatitis B virus RNA is en-capsidated pregenome RNA that may be associated with persistence of viral infection and rebound. J Hepatol. 2016; 65:700–710.
Article
6. Jansen L, Kootstra NA, van Dort KA, et al. Hepatitis B virus pre-genomic RNA is present in virions in plasma and is associated with a response to pegylated interferon Alfa-2a and nucleos(t)ide analogues. J Infect Dis. 2016; 213:224–232.
Article
7. van Bömmel F, Bartens A, Mysickova A, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology. 2015; 61:66–76.
Article
8. Rokuhara A, Matsumoto A, Tanaka E, et al. Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy. J Gastroenterol. 2006; 41:785–790.
Article